Cambrex Introduces Groundbreaking Peptide Synthesis Technology
Cambrex, a leading entity in the contract development and manufacturing organization (CDMO) industry, has made impressive advancements in peptide synthesis technology. They have recently developed an innovative liquid-phase peptide synthesis (LPPS) technology that aims to revolutionize peptide manufacturing. This cutting-edge technology, created by their subsidiary Snapdragon Chemistry, utilizes traditional active pharmaceutical ingredient (API) batch reactors combined with continuous flow methods. This approach eliminates the need for specialized solid-phase reactors, significantly improving overall efficiency.
Advantages of Liquid-Phase Peptide Synthesis
The LPPS technology offers a host of benefits for the manufacturing process. By substantially cutting down on solvent usage and reducing the need for excess reagents, this method not only enhances cost-effectiveness but also responds to environmental issues associated with older methods. Dr. Matt Bio, Cambrex's Chief Scientific Officer, remarked on the company's dedication to research and development, explaining, "Our new LPPS technology provides a significantly more cost-efficient and environmentally sustainable solution when compared to traditional solid-phase peptide synthesis, substantially reducing solvent usage and allowing the substitution of sustainable solvents."
Scalability and Flexibility in Peptide Manufacturing
The adaptability of the LPPS technology is clear, as it can handle peptide chains containing up to 12 residues in length. For larger peptides, a convergent fragment coupling technique is applied during the liquid-phase synthesis. This versatile process can be scaled much like traditional small molecules, making it an appealing choice for various drug development applications.
Enhancing Capabilities in Peptide and Protein Crystallization
In addition to their achievements with LPPS, Cambrex has also developed unique technologies for peptide and protein crystallization. This includes a specialized screening platform that identifies crystalline forms of peptides and proteins, ultimately improving product quality and stability. By minimizing reliance on lengthy preparative chromatography and lyophilization processes, Cambrex is transforming how complex peptides and proteins are manufactured.
The Future of Peptide-Based Therapies
As the clinical and commercial success of peptide-based therapies continues to grow, the demand for efficient manufacturing solutions is more pressing than ever. Thomas Loewald, CEO of Cambrex, highlighted the significance of their innovations by stating, "It's imperative that we provide industry-leading solutions to develop and scale peptide candidates." With a strong focus on research and development, Cambrex plans to invest further in technologies centered on peptides and is also exploring artificial intelligence to enhance oligonucleotide processes.
About Snapdragon Chemistry
Snapdragon Chemistry, a subsidiary of Cambrex, leads in active pharmaceutical ingredient (API) batch and continuous flow process development. Using state-of-the-art automation technology and proprietary equipment, they address complex challenges in process and analytical development. Located in Waltham, Massachusetts, the Snapdragon team comprises over 70 skilled professionals, including 31 PhD scientists, all aiming to build strong ties with the local scientific community.
About Cambrex
Cambrex stands as a global authority in drug substance development and manufacturing. With more than 40 years of experience, they provide thorough support throughout the entire drug lifecycle, including analytical and IND enabling services. The company has a dedicated workforce of 2,000 professionals and serves clients in North America and Europe. Their extensive array of specialized drug substance technologies encompasses continuous flow processes, controlled substances, solid-state science, and material characterization for highly potent APIs.
Frequently Asked Questions
What is liquid-phase peptide synthesis (LPPS)?
LPPS is an innovative technology, introduced by Cambrex, designed to enhance the manufacturing of peptides by minimizing solvent use and improving efficiency compared to traditional methods.
Who developed the new LPPS technology?
The LPPS technology was developed by Snapdragon Chemistry, a subsidiary of Cambrex, with the goal of improving peptide synthesis processes.
What are the advantages of using LPPS?
LPPS provides cost-effectiveness, reduces environmental impact, lowers solvent requirements, and has the ability to scale similarly to conventional small molecule processes.
What does Cambrex specialize in?
Cambrex specializes in contract development and manufacturing services for drug substances, offering support throughout the entire drug lifecycle.
How many employees work at Snapdragon Chemistry?
Snapdragon Chemistry has over 70 employees, including 31 PhD scientists, all committed to advancing pharmaceutical manufacturing technologies.
